2seventy bio, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer treatment
The company harnesses the power of genetics and advanced cellular engineering to create novel therapeutics aimed at addressing unmet medical needs in oncology. By leveraging its proprietary platforms, 2seventy bio works on developing personalized treatment options that target specific tumors and aims to improve patient outcomes through precision medicine. The company's commitment to research and development drives its efforts to bring transformative therapies to market for patients battling various forms of cancer.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.
Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds.
Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in clinical trials. European Commission decision expected in two months.
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval in April.
2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on advancing the technology.
FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard care.
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson & Johnson's Carvykti in second-line multiple myeloma.
Shares of Science Applications International Corporation (NYSESAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates.
